Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT03219593Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Sep 2017
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Bengbu Medical University. Started Sep 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03219593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219593.